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ABSTRACT
Type JIB von Willebrand disease is an autosomal dominant bleeding disorder characterized by the selective loss of high molecular weight von Willebrand factor (vWF) multimers in plasma, presumably due to their abnormally increased reactivity with platelets. We and others have recently identified a panel of missense mutations clustered in the platelet glycoprotein lb binding domain ofvWF from patients with type IIB von Willebrand disease. We now report functional analysis of one of the most frequent type IIB missense mutations, Arg-543 -) Trp (vWF R543W). vWF from a human umbilical vein endothelial cell culture heterozygous for the vWF R543W mutation showed markedly increased binding of large vWF multimers to platelets in the presence of a low dose of ristocetin compared to vWF from a normal control culture. Recombinant vWF containing the vWF R543W mutation expressed in COS-7 cells also demonstrated increased binding of large vWF multimers. Mixed multimers obtained by cotransfection of mutant and wild-type cDNAs showed partial dominance of the vWF R543W mutation. Thus these data demonstrate that the vWF R543W mutation alone is sufficient to confer increased binding of large vWF multimers to platelets in a dominant fashion and that no other factors relating to vWF posttranslational processing or secretion in endothelial cells are requlired for this effect.
von Willebrand factor (vWF) is a multimeric glycoprotein that has several critical roles in hemostasis. In addition to carrying factor VIII in the circulation, vWF binds platelets to the subendothelium at the site of vascular injury to initiate formation of a hemostatic plug. vWF is synthesized in endothelial cells and megakaryocytes as a pre-pro-polypeptide of 2813 amino acids and, subsequently, undergoes extensive posttranslational modifications, including propeptide cleavage, glycosylation, and multimerization. Relatively small vWF multimers are secreted constitutively into the circulation from endothelial cells, whereas the entire spectrum of multimers is stored and released from Weibel-Palade bodies. In plasma, vWF circulates as multimers ranging in size from 400 to 20,000 kDa at a concentration of 5-10 ,ug/ml (1, 2 (4) (5) (6) .
von Willebrand disease (vWD) is an autosomally inherited bleeding disorder resulting from defects in vWF. Qualitative abnormalities in vWF have been associated with the type II variants of vWD (7) . In contrast to the other forms of vWD, patients with type IIB typically present with a variable degree of thrombocytopenia in addition to a moderately severe bleeding disorder (8, 9) . Laboratory evaluation of type JIB patients commonly reveals disproportionately low ristocetin cofactor activities compared to vWF antigen levels in addition to enhanced ristocetin-induced platelet aggregation. Ristocetin is a positively charged antibiotic that induces binding of vWF to platelet GpIb. The highest molecular weight vWF multimers are notably absent from the plasma ofpatients with type JIB vWD, although the full spectrum of multimers is present in platelets (10) . Type IIB vWD must be distinguished from platelet-type vWD (or pseudo-vWD), an intrinsic platelet defect that presents with a nearly identical clinical phenotype. A potential mutation in the GpIb a chain gene has recently been reported in a family with this disorder (11) . In contrast, the defect in type IIB vWD resides within the vWF molecule itself. Plasma high molecular weight vWF multimers of type IIB vWD patients are hypothesized to bind spontaneously to platelets, with subsequent clearance from the circulation (12) accounting for the characteristic multimer pattern and thrombocytopenia. In support of this hypothesis, De Marco and coworkers (13, 14) have demonstrated that vWF purified from a patient with type JIB vWD can induce spontaneous platelet aggregation not seen with normal vWF. This spontaneous platelet aggregation was blocked by a monoclonal antibody against platelet GpIb. Furthermore, vWF secreted from type JIB endothelial cells was shown to contain a full range of vWF multimers and to bind spontaneously to platelets (15) .
We recently reported the identification of four missense mutations occurring within the GpIb binding domain of patients with type IIB vWD (16) . The demonstration of one of these four mutations in each of 14 patients with type IIB vWD from 11 unrelated families, the absence of each of these single nucleotide changes from a large panel of normal DNA samples, and the observation that one of these mutations (vWF R543W) has occurred on at least two distinct genetic backgrounds provided compelling genetic evidence that these mutations are responsible for the type II13 vWD phenotype. Three of the four mutations were also identified in an independent panel of patients by Randi et al. (17) . Recently 
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The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact. (18, 19) . We now report functional analysis of vWF containing the vWF R543W substitution, one of the most common type IIB mutations accounting for approximately one-third of type IIB vWD families. Analysis of vWF containing the R543W substitution obtained from a human umbilical vein endothelial cell (HUVEC) culture and recombinant material expressed in COS-7 cells demonstrates that the single nucleotide substitution resulting in R543W is sufficient to cause the increased binding of large vWF multimers to platelets characteristic of type IIB vWD. METHODS
Expression of Recombinant vWF. The polymerase chain reaction (PCR) was used to amplify exon 28 sequences from patient B1 (16) using primers A and C as described (16, 20) . The Pst I-Bal I fragment (nucleotides 4029-4368 with the adenine of the initiator ATG codon numbered as + 1) was inserted by a series of ligation steps into full-length vWF in the eukaryotic expression vector pMT2 (20) (21) (22) . The entire Pst I-Bal I PCR-derived fragment was sequenced to ensure insertion of the mutation and to exclude PCR errors. Transfection of 20 Ag of plasmid DNA into COS-7 cells was performed as described (21, 22) . Forty hours after transfection, cells were washed twice in phosphate-buffered saline and cultured in 3 ml of serum-free Dulbecco's modified Eagle's medium (JRH Biosciences, Kansas City, MO) containing 0.5% bovine serum albumin, 1% ITS growth supplement (Collaborative Research) in a 100-mm plate. Medium was collected after 24 h and EDTA and phenylmethylsulfonyl fluoride were added to final concentrations of 5 mM and 2 mM, respectively. HUVEC Culture. A HUVEC culture was established from an umbilical cord (23) obtained at birth from patient B5. This HUVEC culture was shown to be heterozygous for the vWF R543W mutation (16) . For preparation of conditioned medium, cells were grown for 24 h in M199 medium (GIBCO) supplemented with heparin (0.1 mg/ml), 0.1% bovine serum albumin, and endothelial cell growth supplement (Collaborative Research; 0.1 mg/ml). Medium was collected and EDTA/phenylmethylsulfonyl fluoride was added as above.
Platelet Binding Assay. The amount of vWF in the cell medium was quantified by a sandwich ELISA as described (21) . Values were normalized to a standard curve generated from purified vWF (kindly provided by P. Bockenstedt, University of Michigan Medical School). For platelet binding, 15 ng of vWF in conditioned medium was incubated with and without formalin-fixed platelets (BioData, Hatboro, PA, 1 x 107 platelets per 100 ,ul of incubation mixture) in the presence or absence of ristocetin in Tris-buffered saline (TBS; 140 mM NaCl/10 mM Tris-HCl, pH 7.5). After a 30-min incubation without stirring, the mixture was layered over a 20% (wt/vol) sucrose cushion and centrifuged for 4 min at 12,000 x g. Quantification of the vWF present before and the vWF left unbound after platelet incubation was performed by ELISA as above.
Multimer Analysis. Conditioned medium was incubated with and without platelets and ristocetin, and the platelets were pelleted through a sucrose gradient as described above. vWF remaining in the supernatant was analyzed by vertical nonreducing agarose gel electrophoresis with minor modifications of the procedure of Raines et al. (24) . After electrophoresis and capillary transfer of material to poly(vinylidene difluoride) membranes (Millipore), membranes were blocked in TN/Blotto [25 mM Tris-HCI, pH 7.5/0.5 M NaCl/5% (wt/vol) Carnation instant milk] for -1 h, incubated with a 1:500 dilution of peroxidase-conjugated rabbit anti-human vWF antibody (Dakopatts, Glostrup, Denmark) in TN/ Blotto, and then washed three times in TNT (25 mM TrisHCI, pH 7.5/0.5 M NaCl/0.1% Triton X-100). Blots were developed using a commercially available kit for chemiluminescence (Amersham) (25) (Fig. 2B) . However, in the presence of low concentrations (0.25 mg/ml) of ristocetin, there was a significant decrease in the amount of large mutant HUVEC vWF multimers remaining in the supernatant after platelet incubation compared to the normal control. With ristocetin at 1 mg/ml, nearly all of the mutant vWF was cleared from the supernatant.
To determine whether the R543W substitution alone was sufficient to account for the observed increased platelet binding of mutant HUVEC vWF, recombinant vWF containing the R543W substitution (vWF R543W) was expressed by transient transfection of COS-7 cells and compared to wildtype vWF. vWF R543W exhibited slight spontaneous platelet binding and markedly increased platelet binding in the presence of low concentrations of ristocetin (Fig. 1B) . Additionally, vWF obtained by a cotransfection of a 1:1 mixture of vWF R543W and wild-type vWF DNA constructs showed enhanced platelet binding in the presence of a low dose of ristocetin that was intermediate to that of wild-type and pure mutant vWF. No vWF was detected in medium from COS-7 cells transfected with the control pMT2 vector alone and ristocetin in the absence of platelets did not result in clearance of vWF from the supernatant (data not shown).
Multimer analysis of nonreduced recombinant vWF containing the R543W mutation also showed no spontaneous platelet binding (Fig. 3) . However, there was a selective loss of the high molecular weight multimers after incubation with platelets in the presence of low concentrations of ristocetin (0.25 mg/ml). No such change was evident with the recombinant wild-type vWF control under the same conditions. DISCUSSION Type IIB is distinguished from other forms of vWD by enhanced ristocetin-induced platelet aggregation and often by thrombocytopenia. Gralnick et al. (27) have described four patients exhibiting a type TIB vWD phenotype with the additional feature of spontaneous platelet aggregation. Analysis of purified vWF from one of the four patients revealed an -5wo reduction in the sialic acid and galactose concentration (27) . Asialo-vWF had been shown (28, 29) DeMarco et al. (14) showed that type IIB vWF purified from patient plasma bound to platelets with greater affinity than normal vWF despite absent high molecular weight multimers in the former. Our data demonstrate that this increased affinity is most marked for high vWF multimers. This could be due to a simple additive effect of the multiple platelet binding sites present in these large multimers or possible cooperativity between individual binding sites. These observations are consistent with previous studies of fractionated normal plasma vWF multimers (35, 36) .
Cotransfection studies using a 1:1 molar mixture of mutant and wild-type DNA demonstrate that vWF R543W is partially dominant over wild-type vWF in vitro. This is consistent with the apparent autosomal dominant inheritance of most cases of type IIB vWD and also suggests that the homozygous state might result in a more severe clinical phenotype. Such homozygosity for type IIB vWD has not yet been described and could potentially be lethal. There has been one report of a family with two daughters with type IIB vWD from two phenotypically normal parents (37) . It is possible that the genetic abnormality in this family is autosomal recessive, with each parent having a subclinical type IIB vWD defect that is only evident in the homozygous state. Alternatively, this could represent germinal mosaicism as demonstrated in another type IIB vWD family (38) .
Human diseases due to quantitative and/or qualitative loss of a functional protein can arise from multiple distinct molecular defects including point mutations and gene deletions. In the best studied example, the hemoglobinopathies, more than 200 mutations have been reported in the 146-amino acid human 83-globin chain (39) . However, the unique sickle cell anemia phenotype is always due to the same nucleotide substitution in codon 6, although this mutation appears to have arisen at least four times. By analogy, the common quantitative type I and III vWD phenotypes might be expected to occur through a large number of distinct molecular defects, whereas only a limited number of missense mutations may have the potential to produce the unique "gainof-function" of type IIB vWD. Consistent with this hypothesis, a panel of four missense mutations accounts for >90%o of type IIB vWD patients (16) (17) (18) (19) and several of these mutations have occurred by independent mutational events (16, 17) . The apparent small number of potential type IIB vWD mutations should facilitate the development of highly sensitive and specific DNA-based diagnosis and classification for this disorder.
